GH Guardant Health, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

—

Period return

—

Volume

—

There isn’t enough historical data to display yet.

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 29.Highin 8 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 28.LowBUY2 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 05. 26.LowBUY2 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.12%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.33%
2026. 05. 09.LowBUY2 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 05. 09.LowBUY2 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 05. 08.LowHOLD2 months ago
Evercore ISI Group: In-Line
US analyst rating / recommendation change.
2026. 04. 15.LowBUY3 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 04. 07.LowHOLD4 months ago
Evercore ISI Group: In-Line
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $131.24 · 21 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 29.	After market close (AMC)	$-0.39	—	—	$314.97M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.77	—	—	$203.47M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-2.66	—	—	$537.2M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-1.78	—	—	$345.73M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	4,229,531	$390.68M	0.33%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	2,171,903	$221.84M	0.35%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	1,499,169	$153.13M	0.25%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	695,940	$64.28M	0.12%	—	New position

Guardant Health, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 28.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 05. 26.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 05. 09.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight
2026. 05. 09.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 05. 08.	Evercore ISI Group	—	Maintain	In-Line → In-Line	—	Evercore ISI Group: In-Line
2026. 04. 15.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight